Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Exicure Inc (XCUR)

Exicure Inc (XCUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld Business Wire - Thu May 4, 2023

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that it...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors Business Wire - Thu Apr 27, 2023

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that,...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update Business Wire - Mon Mar 27, 2023

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors Business Wire - Fri Feb 24, 2023

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the closing...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements Business Wire - Wed Dec 14, 2022

Exicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the termination...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update Business Wire - Mon Nov 14, 2022

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives Business Wire - Mon Sep 26, 2022

Exicure, Inc. (NASDAQ: XCUR) today announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value. After a strategic review...

XCUR : 0.5150 (-4.68%)
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference Business Wire - Thu Sep 1, 2022

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress Business Wire - Mon Aug 15, 2022

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological...

XCUR : 0.5150 (-4.68%)
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement Business Wire - Wed Jul 20, 2022

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological...

XCUR : 0.5150 (-4.68%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip Barchart - Wed Apr 24, 6:30PM CDT
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot